Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM08502 (Cirtuvivint) in combination with SOC in advanced solid tumors
NCT05084859Phase 1Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cirtuvivint in castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Treatment Emergent Adverse Events, Maximum Tolerated Dose and 2 more. Started Nov 2021; status: terminated.
02
Drugs
cirtuvivint
03
Conditions
castration-resistant prostate cancer (CRPC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05084859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084859.